Oxford Spin-Out OMass Just Raised $298M—Here's Why Investors Are All In

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford University, just closed an oversubscribed $298 million (€275 million) Series C round. That's a hefty vote of confidence for a company developing small-molecule drugs against targets that have long been considered undruggable. ### Who Put Up the Money? The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. They were joined by Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. And every existing investor came back for more—Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. When your entire cap table re-ups, that's a signal. ### What OMass Actually Does Founded in 2016, OMass grew out of Professor Dame Carol Robinson's lab at Oxford. The goal? Translate native mass spectrometry research into new small-molecule therapeutics for historically challenging targets. Its proprietary OdyssION platform combines next-gen native mass spectrometry, novel biochemistry, and custom chemistry. The result: it can interrogate drug targets within their native ecosystems, giving you cell-system fidelity with cell-free precision. Ros Deegan, CEO of OMass, put it this way: *"This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow. We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic."* ### The Pipeline: OMS1620 and Beyond The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist. It's heading into Phase 2 trials for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. OMS1620 was designed to increase receptor residency time and maintain activity. If it works, it could be a game-changer for patients with these rare endocrine disorders. And there's more in the pipeline. An SLC15A4 inhibitor is next in line, also targeting immunology. The company has built a reputation for delivering first- and best-in-class programs in endocrinology and immunology. ### The Bigger Picture: European Biotech Is Heating Up OMass' round is part of a wave of significant therapeutics funding in Europe this year. Here's a quick rundown: - **France:** Bionyra Pharma secured $155 million (€143 million) for inflammatory disease treatments. - **Denmark:** Breye Therapeutics raised $73 million (€67.5 million) for its oral small-molecule pipeline, in a round co-led by Novo Holdings. - **UK:** Cambridge-based STORM Therapeutics secured $51.5 million (€47.5 million), Microbiotica raised $45.5 million (€42 million), Glasgow-based Mironid received $43.2 million (€39.9 million), and London-based Alchemab Therapeutics secured $31.7 million (€29.3 million). - **Netherlands:** Laigo Bio added $6 million (€5.5 million). Together, these deals represent roughly $406 million (€374.7 million) in new financing during 2026. Include OMass' round, and that jumps to about $704 million (€649.7 million). Investors are clearly hungry for innovative therapeutics. As Evan Greif, Principal at Bain Capital Life Sciences, said: *"OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs."* ### What's Next for OMass? The proceeds will push OMS1620 through Phase 2 clinical development. If successful, it could transform treatment for CAH and Cushing's syndrome. The company is also advancing its SLC15A4 inhibitor and broader pipeline. Max Klement, Partner at Novo Holdings, added: *"We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic."* With a fresh $298 million and a syndicate of top-tier investors, OMass is well-positioned to make a real impact on patients' lives. And it's a reminder that Europe's biotech scene is thriving—something worth keeping an eye on.